Safety and Efficacy of Belimumab in Patients with Lupus Nephritis

Clin J Am Soc Nephrol. 2022;17:1620–1630 doi: 10.2215/CJN.02520322

This 28-week, open-label extension of BLISS-LN found no new safety signals and maintained efficacy with belimumab, in patients with lupus nephritis.

Read more…

Belimumab Use During Pregnancy: Interim Results of the Belimumab Pregnancy Registry

Birth Defects Res. 2022. Epub ahead of print doi: 10.1002/bdr2.2091

There was no pattern or common mechanism of birth defects associated with belimumab within the Belimumab Pregnancy Registry (BPR) data.

Read more…

Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus

N Engl J Med. 2022;387(10):894–904 doi: 10.1056/NEJMoa2118025

Phase 2 study, in patients with systemic lupus erythematosus, shows that litifilimab is associated with a greater reduction from baseline in the number of swollen and tender joints than placebo, over a period of 24 weeks.

Read more…

Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature

Autoimmun Rev. 2022 doi: 10.1016/j.autrev.2022.103188

Gomez, et al. summarise the effects of biological therapies on SLE patients' health-related quality of life (HRQoL) in RCT and real-life settings, based on a systematic search of the literature.

Read more…

Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus

N Engl J Med. 2022;387(4):321–331 doi: 10.1056/NEJMoa2118024

Phase II study, in patients with active cutaneous lupus erythematosus, shows that litifilimab improved scores on a measure of skin disease activity, over 16 weeks, compared to placebo.

Read more…

Effect and safety profile of belimumab and tacrolimus combination therapy in thirty‑three patients with systemic lupus erythematosus

Clin Rheumatol. 2022. Epub ahead of print doi: 10.1007/s10067-022-06325-6

A single-centre analysis of patients with SLE administered tacrolimus and belimumab shows this combination therapy to be well-tolerated, with a good efficacy profile and glucocorticoid-reducing effect.

Read more…

Trajectory of Damage Accrual in Systemic Lupus Erythematosus based on Ethnicity and Socioeconomic Factors

J Rheumatol. 2022. Epub ahead of print doi: 10.3899/jrheum.211135

Large study confirms that cumulative damage accrual is faster in African-Americans, compared to Caucasians, highlighting that ethnicity plays the major role in damage accrual, regardless of socioeconomic status.

Read more…